The Global InfluenzaVaccines Market, by Vaccine Type (Trivalent Vaccines and QuadrivalentVaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by AgeGroup (Pediatrics and Adults) and by Region (North America, Latin America,Europe, Asia Pacific, Middle East, and Africa) estimated to be valued at US$3,991.4 billion in 2017, and is projected to exhibit a CAGR of 4.4% over theforecast period (2018 – 2026).
Rising pipeline product to comeup with new vaccine product as a part of key organic strategies by marketplayers. For instance, 2017, Seqirus’s FLAUD, first and only adjuvant-basedtrivalent influenza vaccine, received MHRA approval against influenza virus inolder aged people (adults aged 65 and above). In same year, Seqirus entered inthe U.S market with its influenza vaccine portfolio, with over 50 million dosesfor protection against seasonal influenza of 2017-2018. The portfolio includesFLAUD, FLUCELVAX QUADRIVALENT, AFLURIA QUADRIVALENT, AFLURIA, and FLUVIRIN.Moreover, in 2017, FluGen, Inc., received US$ 14.4 million by Department ofDefense for evaluating Universal Flu Vaccine, RedeeFlu, of Mismatched Strains.In Sep 2017, Novavax initiating phase1/2 clinical trials for nanoparticleseasonal influenza vaccine in older adults. In April 2018, BiodVaxPharmaceuticals LTD., started enrollment of patients for phase 2 clinicaltrials for universal flu vaccine candidate, M-001.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1705
Browse Market Data 32 Tables and30 Figures spread through 150 Pages and in-depth TOC on "InfluenzaVaccines Market, by Vaccine Type (Trivalent Vaccines and QuadrivalentVaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by AgeGroup (Pediatrics and Adults) and by Region - Global Forecast to 2026”
Increasing prevalence of seasonalinfluenza in pediatric population is propelling demands for development of newvaccines. Influenza is estimated to infect 5% and 10% of adults and 20 to 30%of children. Moreover, companies are engaged in producing vaccines throughinnovative technologies such as egg-based, cell-based, and recombinant-basedproduct for reducing the gap between demand and supply. Furthermore, increasingawareness and initiatives to increase the vaccine coverage is helping in marketgrowth. The 2017 – 2018 recommendations guidelines by the Advisory Committee onImmunization Practices (ACIP) mentions routine annual influenza vaccination foreveryone aged older than 6 months. However, high cost of vaccine development isexpected to hinder growth of the market over the forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/influenza-vaccines-market-1705
Key takeaways of the InfluenzaVaccines Market:
The global influenza vaccinesmarket is expected to expand at a CAGR of 4.4% during the forecast period (2018– 2026), owing to increasing R&D activities of market players.
Trivalent vaccine is expected todominate vaccine type segment, owing to more number of products
Influenza type A virus segment isexpected to be predominant, owing to increasing prevalence of type A basedinfection
Pediatric being more susceptibleto influenza virus is expected to lead age group segment
Some of the major playersinvolved in global influenza vaccines market include Seqirus Vaccines Limited,GlaxoSmithKline plc
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1705
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
